Abstract
Cytochrome P450s (CYPs) reaction phenotyping is a technique used to identify the major enzyme(s) responsible for the metabolism of a new molecular entity in order to assess clinical drug–drug interaction potential and estimate its relative contribution to the overall metabolic clearance in human. CYP phenotyping is commonly carried out using recombinant CYPs, and/or human liver microsomes (HLM) in combination with isoform-specific chemical inhibitors. For drug candidates with both CYP- and non-CYP-mediated metabolism, human hepatocytes can be a preferred in vitro system for enzyme reaction phenotyping. The protocol described here mainly focuses on the eight common CYP isoforms (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) using both recombinant enzymes and HLM as the in vitro system, respectively. These rapid approaches provide qualitative information about the CYP involvement in metabolic clearance of a drug candidate, which can be followed by a more in-depth characterization of metabolic reactions using alternative in vitro systems as needed when the compound is advanced to the next stage of development.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Guengerich FP (2008) Cytochrome 450 and chemical toxicology. Chem Res Toxicol 21:70–83
Harper TW, Brassil PJ (2008) Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates. AAPS J 10(1):200–207
Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141
Cheng Y, Ma L, Chang SY, Humphreys WG, Li W (2016) Application of static models to predict midazolam clinical interactions in the presence of single or multiple hepatitis C virus drugs. Drug Metab Dispos 44(8):1372–1380
Achour B, Barber J, Rostami-Hodjegan A (2014) Expression of hepatic drug-metabolizing cytochrome P450 enzymes and their intercorrelations: a meta-analysis. Drug Metab Dispos 41:1349–1356
Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N (2015) Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification. Drug Metab Dispos 43(11):1823–1837
Li D (2017) Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opin Drug Discovery 12(11):1105–1115
Zientek MA, Youdim K (2015) Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos 43:163–181
Walsky RL, Obach RS, Hyland R, Kang P, Zhou S, West M, Geoghegan KF, Helal CJ, Walker GS, Goosen TC, Zientek MA (2012) Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab Dispos 40(9):1686–1697
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Wong, S., Yan, Z. (2021). In Vitro Reaction Phenotyping of Cytochrome P450 Enzymes. In: Yan, Z., Caldwell, G.W. (eds) Cytochrome P450. Methods in Pharmacology and Toxicology. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-1542-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-0716-1542-3_18
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-1541-6
Online ISBN: 978-1-0716-1542-3
eBook Packages: Springer Protocols